27 August 2021
Change in Director's Interest Notice - L Cheng
26 August 2021
Appendix 4G – Corporate Governance Statement
26 August 2021
Starpharma annual report and full year financial results
23 August 2021
VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
17 August 2021
VIRALEZE™ well tolerated in multiple dose clinical study
2 August 2021
Initial Director's Interest Notice
30 July 2021
Quarterly Cashflow and Activities Report
29 July 2021
Resignation of non-executive director
28 July 2021
Lynda Cheng appointed as non-executive director
27 July 2021
Starpharma to present DEP® platform at CRS Annual Meeting
27 July 2021
VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant
5 July 2021
TGA infringement notices for alleged advertising
2 July 2021
Change in substantial holding
24 June 2021
Starpharma to present at Virtual Life Sciences Investor Forum
21 June 2021
VIRALEZE UK update
18 June 2021
VIRALEZE SPL7013 virucidal against multiple COVID variants
11 June 2021
VIRALEZE antiviral nasal spray registered for sale in India
1 June 2021
VIRALEZE SPL7013 highly active in UK variant of coronavirus
11 May 2021
VIRALEZE™ partners with Harlequins in the UK
6 May 2021
VIRALEZE™ launches in Europe

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.